Drug manufacturers continue to expand claims-data requirements under the 340B Drug Pricing Program. In a recent article, Healthcare Financial Management Association (HFMA) examines Johnson & Johnson’s (J&J) new policy requiring certain covered entities to submit claims data to maintain access to 340B pricing, adding to the operational and compliance challenges facing 340B providers.
The article highlights analysis from Frier Levitt attorney Benjamin Youssef who discusses the growing use of manufacturer claims-data mandates and what covered entities should consider as these policies evolve. His analysis emphasizes the importance of understanding manufacturer-specific requirements, monitoring compliance deadlines, and documenting any resulting restrictions on 340B pricing.
